Ofatumumab-based Consolidation Appears Effective for CLL

Share this content:
Ofatumumab-based consolidation therapy appears to be efficacious for and well-tolerated by patients with chronic lymphocytic leukemia.
Ofatumumab-based consolidation therapy appears to be efficacious for and well-tolerated by patients with chronic lymphocytic leukemia.

Ofatumumab-based consolidation therapy appears to be efficacious for and well-tolerated by patients with chronic lymphocytic leukemia (CLL), according to study published in the journal The Lancet Haematology.1

Ofatumumab, a human type I anti-CD20 monoclonal antibody, is approved by the U.S. Food and Drug Administration as maintenance therapy for patients with recurrent or progressive CLL who have achieved a complete or partial response after at least 2 lines of treatment. Researchers assessed whether efficacy could be improved if ofatumumab were used as a consolidation strategy.

For this phase 2 study, investigators enrolled patients with previously untreated CLL and assigned them to 1 of 2 treatment arms. In the first arm, which was previously reported, patients received 6 cycles of induction with pentostatin 2 mg/m2 on day 1, cyclophosphamide 600 mg/m2 on day 1, and ofatumumab intravenously every 21 days. During cycle 1, ofatumumab was administered at a dose of 300 mg on day 1 and 1000 mg/m2 on day 2, followed by 1000 mg/m2 on day 1 during cycles 2 to 6.

In the second arm, 34 patients received the same regimen as in the first arm, in addition to 6 cycles of ofatumumab consolidation at a dose of 1000 mg intravenously once every 4 weeks.

Thirty-one of the 34 patients completed induction and started consolidation, and 26 patients completed the 6 planned cycles of ofatumumab consolidation. The 18-month treatment-free survival rate was 94.1% (95% CI, 78.5-98.5).

RELATED: Lenalidomide With Rituximab Shows Activity on Refractory CLL

Grade 3 or worse adverse events at least potentially related to ofatumumab consolidation were neutropenia (41%), infection (6%), anemia (3%), hemolysis (3%), fatigue (3%), and a neurologic, metabolic, respiratory, and vascular complication (each in 3%).                     

Reference

  1. Strati P, Lanasa M, Call TG, et al. Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. Lancet Haematol. 2016 Aug 1. doi: 10.1016/S2352-3026(16)30064-3 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters